"I like the scientific spirit -the holding off, the being sure but not too sure, the willingness to surrender ideas when the evidence is against them: this is ultimately fine -it always keeps the way beyond open -always gives life, thought, affection, the whole man, a chance to try over again after a mistake -after a wrong guess".
Walt Whitman: American poet, essayist, journalist and humanist -often called the father of free verse. Born May 1819 -Died March 1892
Significant advances towards precision or personalised medicine are ongoing and the "one size fits all" approach which has been successful thus far is not suitable or ideal for all patients. A pursuit that takes into account the individual traits and differences, ranging from a basic individual response to a highly specific personalised response, should be the goal. Competitive advances have already been accomplished, e.g., genome wide analysis, etc that have laid the path to individualization, e.g., patients with malignancies undergoing molecular testing to select specific treatment with the best chance for survival or minimise side effects.
Governments/individuals around the world have initiated developments in the direction of individualised medicine; also collecting data supporting individualisation. Evidence for personalisation can be a review or, ideally, a prospective trial. Scientists, physicians and researchers have to be lauded for their efforts to conduct a review, a clinical trial or an ethically approved experiment or comparison. The important thing is not to take the short cut or jump to a conclusion without adequate evidence of efficacy and safety and/or an authoritative review/trial. My congratulations to authors who have been through the rigorous process of peer review and been successful in manuscript publication. Pan et al. analyse high plasma free haemoglobin with a retrospective review over a five year period; Itoh et al. conduct a prospective randomised trial comparing the clinical effectiveness and biocompatibility of heparin-coated circuits and PMEA-coated circuits in the paediatric cardiac population. As I have alluded to, a review or a prospective randomised trial are two mechanisms which select evidence appropriately to progress science towards the individualised approach. Mosca et al. compare the duration of conventional cardiopulmonary resuscitation prior to extracorporeal cardiopulmonary resuscitation with survival in adult patients with cardiac arrest. This knowledge will enhance selecting an appropriate duration which can be identified with conventional cardiopulmonary resuscitation for an increase in the number of survivors. Bienz and colleagues analyse the microcirculatory response during on-pump coronary artery bypass grafting surgery and compare it with off-pump coronary artery bypass grafting surgery. Guo et al. look at the advancing field of minimal thoracoscopic repair of atrial septal defects using bilateral subclavian vein sheaths for superior vena caval drainage and compare the cosmetic, safety and clinical effectiveness, as well as outcome. McNair and colleagues review bivalirudin as an adjunctive anticoagulant to heparin in the treatment of heparin resistance, which is encountered occasionally, and is an important adjunct available in patients with heparin resistance. Akin et al. look at the relationship of platelet indices to the severity of coronary artery disease in patients undergoing primary percutaneous coronary intervention, again an example of physicians and scientists wanting to enhance our learning to target appropriate management. Swol et al. also review the conditions and procedures for in-hospital extracorporeal life support in the cardiopulmonary resuscitation of adult patients, hopefully, leading the path to an improvement in the standardised protocol for in-hospital extracorporeal life support. I hope continuing advances in different specialities will pave the way for an individualistic, customised approach that will ultimately lead to enhanced survival, treatment and/or cure for our patients. 
